{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:43:28Z","timestamp":1791269008682,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00432-022-04352-z","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T17:02:56Z","timestamp":1663261376000},"page":"4411-4417","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma"],"prefix":"10.1007","volume":"149","author":[{"given":"Ciro","family":"Franzese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Baldaccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Badalamenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierina","family":"Navarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Bellu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Comito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Clerici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ausilia","family":"Teriaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Massaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Di Cristina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Lo Faro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Tomatis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Scorsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"key":"4352_CR1","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.euo.2019.08.012","volume":"4","author":"C Berghen","year":"2021","unstructured":"Berghen C et al (2021) Progression-directed therapy for oligoprogression in castration-refractory prostate cancer. Eur Urol Oncol 4:305\u2013309","journal-title":"Eur Urol Oncol"},{"key":"4352_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424","journal-title":"CA Cancer J Clin"},{"key":"4352_CR3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.eururo.2021.07.026","volume":"80","author":"P Cheung","year":"2021","unstructured":"Cheung P et al (2021) Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: a phase 2 prospective multicenter study. Eur Urol 80:693\u2013700","journal-title":"Eur Urol"},{"key":"4352_CR4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/bju.15541","volume":"129","author":"B De","year":"2022","unstructured":"De B et al (2022) Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU Int 129:610\u2013620","journal-title":"BJU Int"},{"key":"4352_CR5","doi-asserted-by":"publisher","first-page":"e170","DOI":"10.1016\/S1470-2045(13)70569-2","volume":"15","author":"G de Meerleer","year":"2014","unstructured":"de Meerleer G et al (2014) Radiotherapy for renal-cell carcinoma. Lancet Oncol 15:e170\u2013e177","journal-title":"Lancet Oncol"},{"key":"4352_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.euo.2020.05.004","volume":"4","author":"MP Deek","year":"2021","unstructured":"Deek MP et al (2021) Metastasis-directed therapy prolongs efficacy of systemic therapy and improves clinical outcomes in oligoprogressive castration-resistant prostate cancer. Eur Urol Oncol 4:447\u2013455","journal-title":"Eur Urol Oncol"},{"key":"4352_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.juro.2018.08.049","volume":"201","author":"C Franzese","year":"2019","unstructured":"Franzese C et al (2019) Role of stereotactic body radiation therapy for the management of oligometastatic renal cell carcinoma. J Urol 201:70\u201376","journal-title":"J Urol"},{"key":"4352_CR8","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10585-021-10131-w","volume":"38","author":"C Franzese","year":"2021","unstructured":"Franzese C et al (2021) The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group. Clin Exp Metastasis 38:527\u2013537","journal-title":"Clin Exp Metastasis"},{"key":"4352_CR9","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.clon.2021.12.021","volume":"34","author":"C Franzese","year":"2022","unstructured":"Franzese C et al (2022a) Risk-group classification by recursive partitioning analysis of patients affected by oligometastatic renal cancer treated with stereotactic radiotherapy. Clin Oncol 34:379\u2013385","journal-title":"Clin Oncol"},{"key":"4352_CR10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10585-022-10158-7","volume":"39","author":"C Franzese","year":"2022","unstructured":"Franzese C et al (2022b) Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients\u2019 selection. Clin Exp Metastasis 39:449\u2013457","journal-title":"Clin Exp Metastasis"},{"key":"4352_CR11","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M et al (2020) Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 21:e18\u2013e28","journal-title":"Lancet Oncol"},{"key":"4352_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.euo.2021.12.001","volume":"5","author":"R Hannan","year":"2022","unstructured":"Hannan R et al (2022) Phase II trial of stereotactic ablative radiation for oligoprogressive metastatic kidney cancer. Eur Urol Oncol 5:216\u2013224","journal-title":"Eur Urol Oncol"},{"key":"4352_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/COC.0000000000000622","volume":"43","author":"L He","year":"2020","unstructured":"He L et al (2020) Survival outcomes after adding stereotactic body radiotherapy to metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Am J Clin Oncol 43:58\u201363","journal-title":"Am J Clin Oncol"},{"key":"4352_CR14","doi-asserted-by":"publisher","first-page":"6605","DOI":"10.1038\/ncomms7605","volume":"6","author":"MKH Hong","year":"2015","unstructured":"Hong MKH et al (2015) Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun 6:6605","journal-title":"Nat Commun"},{"key":"4352_CR15","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.urology.2011.05.012","volume":"78","author":"SP Kim","year":"2011","unstructured":"Kim SP et al (2011) Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology 78:1101\u20131106","journal-title":"Urology"},{"key":"4352_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-021-02574-0","author":"G Marvaso","year":"2021","unstructured":"Marvaso G et al (2021) Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how? Clin Transl Oncol. https:\/\/doi.org\/10.1007\/s12094-021-02574-0","journal-title":"Clin Transl Oncol"},{"key":"4352_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2018.04.008","volume":"98","author":"E Meyer","year":"2018","unstructured":"Meyer E et al (2018) Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: a study of the Getug group. Eur J Cancer 98:38\u201347","journal-title":"Eur J Cancer"},{"key":"4352_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.6004\/jnccn.2014.0018","volume":"12","author":"RJ Motzer","year":"2014","unstructured":"Motzer RJ et al (2014) Kidney cancer, version 2.2014. J Natl Compr Cancer Netw 12:175\u2013182","journal-title":"J Natl Compr Cancer Netw"},{"key":"4352_CR19","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2519::AID-CNCR26>3.0.CO;2-E","volume":"80","author":"S Ning","year":"1997","unstructured":"Ning S, Trisler K, Wessels BW, Knox SJ (1997) Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 80:2519\u20132528","journal-title":"Cancer"},{"key":"4352_CR20","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/pros.24132","volume":"81","author":"C Onal","year":"2021","unstructured":"Onal C et al (2021) Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone\/enzalutamide treatment. Prostate 81:543\u2013552","journal-title":"Prostate"},{"key":"4352_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s10585-021-10126-7","volume":"38","author":"D Pezzulla","year":"2021","unstructured":"Pezzulla D et al (2021) Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials. Clin Exp Metastasis 38:519\u2013526","journal-title":"Clin Exp Metastasis"},{"key":"4352_CR22","doi-asserted-by":"publisher","first-page":"100708","DOI":"10.18632\/oncotarget.20022","volume":"8","author":"D Santini","year":"2017","unstructured":"Santini D et al (2017) Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis. Oncotarget 8:100708\u2013100716","journal-title":"Oncotarget"},{"key":"4352_CR23","doi-asserted-by":"publisher","first-page":"E257","DOI":"10.1016\/j.ijrobp.2019.06.1957","volume":"105","author":"J Schoenhals","year":"2019","unstructured":"Schoenhals J et al (2019) Stereotactic ablative radiotherapy for oligoprogressive metastatic renal cell carcinoma. Int J Radiat Oncol Biol Phys 105:E257","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4352_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2021.100692","volume":"6","author":"JE Schoenhals","year":"2021","unstructured":"Schoenhals JE et al (2021) Stereotactic ablative radiation therapy for oligoprogressive renal cell carcinoma. Adv Radiat Oncol 6:100692","journal-title":"Adv Radiat Oncol"},{"key":"4352_CR25","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.21037\/jtd-2019-pm-10","volume":"13","author":"J Seitlinger","year":"2021","unstructured":"Seitlinger J, Prieto M, Siat J, Renaud S (2021) Pulmonary metastasectomy in renal cell carcinoma: a mainstay of multidisciplinary treatment. J Thorac Dis 13:2636\u20132642","journal-title":"J Thorac Dis"},{"key":"4352_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.radonc.2020.07.035","volume":"151","author":"CM Sha","year":"2020","unstructured":"Sha CM et al (2020) Toxicity in combination immune checkpoint inhibitor and radiation therapy: a systematic review and meta-analysis. Radiother Oncol 151:141\u2013148","journal-title":"Radiother Oncol"},{"key":"4352_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00528-3","author":"C Tang","year":"2021","unstructured":"Tang C et al (2021) Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(21)00528-3","journal-title":"Lancet Oncol"},{"key":"4352_CR28","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/sj.bjc.6603327","volume":"95","author":"UM Vogl","year":"2006","unstructured":"Vogl UM et al (2006) Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer 95:691\u2013698","journal-title":"Br J Cancer"},{"key":"4352_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.radonc.2005.03.022","volume":"77","author":"PJ Wersall","year":"2005","unstructured":"Wersall PJ et al (2005) Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol 77:88\u201395","journal-title":"Radiother Oncol"},{"key":"4352_CR30","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.bone.2010.09.008","volume":"48","author":"E Woodward","year":"2011","unstructured":"Woodward E et al (2011) Skeletal complications and survival in renal cancer patients with bone metastases. Bone 48:160\u2013166","journal-title":"Bone"},{"key":"4352_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.932637","author":"A Yaney","year":"2022","unstructured":"Yaney A et al (2022) Radiotherapy in oligometastatic, oligorecurrent and oligoprogressive prostate cancer: a mini-review. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2022.932637","journal-title":"Front Oncol"},{"key":"4352_CR32","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.euo.2019.05.007","volume":"2","author":"NG Zaorsky","year":"2019","unstructured":"Zaorsky NG, Lehrer EJ, Kothari G, Louie AV, Siva S (2019) Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. Eur Urol Oncol 2:515\u2013523","journal-title":"Eur Urol Oncol"},{"key":"4352_CR33","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ijrobp.2019.07.023","volume":"105","author":"Y Zhang","year":"2019","unstructured":"Zhang Y et al (2019) Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer. Int J Radiat Oncol Biol Phys 105:367\u2013375","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04352-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04352-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04352-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T14:06:40Z","timestamp":1689430000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04352-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4352"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04352-z","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,15]]},"assertion":[{"value":"24 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}